Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 · kind B2 · utility
5Cited by
16References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 22, 2003 |
| Grant date | Mar 13, 2007 |
| Priority date | — |
| Expiry date | Sep 22, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.